Approval · Notice of Compliance 13474 · 2012
VOTRIENT: Notice of Compliance 13474
Issued July 12, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13474
- Date
- July 12, 2012
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: For the treatment of adult patients with selective subtypes of advanced Soft TIssue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy. Patients were required to have diseasee progression on or after, or be intolerant to, an anthracyline-based regimen in the pivotal pahse III study in STS
- Therapeutic class
- Antineoplastic Agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VOTRIENT | Not yet assigned | — |
Medicinal ingredients
- PAZOPANIB HYDROCHLORIDE 200 MG per TAB
- PAZOPANIB HYDROCHLORIDE 400 MG per TAB